COMPARATIVE STUDY
JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

New therapies and preventive strategies to treat and minimize damage in lupus.

Systemic lupus erythematosus is a complex disease characterized by a loss of immune tolerance leading to autoantibody production, immune complex deposition in target organs, and resultant tissue damage. There are currently only three medications approved for the treatment of lupus; hydroxychloroquine, aspirin, and prednisone. This limited spectrum of medications is contrasted by the dozen clinical trials in lupus underway or planned for the next 2 years. These new therapeutic agents hold promise for being more effective with fewer side effects than the current available agents. Increased awareness of co-morbid diseases in lupus is also leading to new approaches for the prevention of "disease damage" in lupus.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app